🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million new cases annually. Especially elevated rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists hope that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization represents a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which uses a dual-drug approach. The study included nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in many developing nations.

Medical professionals treating patients have voiced positive views. The availability of a single-dose, oral treatment such as this is described as a "game-changer" for managing the epidemic. This is viewed as essential to lessen the impact of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea globally.